- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2012 (2012), Article ID 798634, 8 pages
Androgen Metabolism Gene Polymorphisms, Associations with Prostate Cancer Risk and Pathological Characteristics: A Comparative Analysis between South African and Senegalese Men
1Department of Urology, Stellenbosch University, P.O. Box 19063, Cape Town 7505, South Africa
2Department of Biostatistics and Epidemiology and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
3Department of Urology, Tygerberg Hospital, Cape Town 7505, South Africa
4University Cheikh Anta Diop and Hôpital Général de Grand Yoff, Dakar, Senegal
Received 25 May 2012; Revised 3 August 2012; Accepted 20 August 2012
Academic Editor: Camille Ragin
Copyright © 2012 Pedro Fernandez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, vol. 127, no. 12, pp. 2893–2917, 2010.
- A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011.
- M. M. Center, A. Jemal, J. Lortet-Tieulent et al., “International variation in prostate cancer incidence and mortality rates,” European Urology, vol. 61, no. 6, pp. 1079–1092, 2012.
- N. B. Delongchamps, A. Singh, and G. P. Haas, “Epidemiology of prostate cancer in Africa: another step in the understanding of the disease?” Current Problems in Cancer, vol. 31, no. 3, pp. 226–236, 2007.
- E. A. Platz and E. Giovannucci, “Prostate cancer,” in Cancer Epidemiology and Prevention, D. Schottenfeld and J. F. Fraumeni, Eds., pp. 1128–1150, Oxford University Press, New York, NY, USA, 2006.
- F. T. Odedina, T. O. Akinremi, F. Chinegwundoh et al., “Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa,” Infectious Agents and Cancer, vol. 4, supplement 1, article S2, 2009.
- D. M. Parkin, F. Sitas, M. Chirenje, L. Stein, R. Abratt, and H. Wabinga, “Part I: cancer in indigenous Africans-burden, distribution, and trends,” The Lancet Oncology, vol. 9, no. 7, pp. 683–692, 2008.
- A. Jemal, F. Bray, D. Forman et al., “Cancer burden in Africa and opportunities for prevention,” Cancer, vol. 118, no. 18, pp. 4372–4384, 2012.
- E. de Wit, W. Delport, C. E. Rugamika et al., “Genome-wide analysis of the structure of the South African Coloured Population in the Western Cape,” Human Genetics, vol. 128, no. 2, pp. 145–153, 2010.
- N. Mqoqi, P. Kellett, F. Sitas, and M. Jula, “Incidence of histologically diagnosed cancer in South Africa, 1998-1999,” in National Cancer Registry Johannesburg, National Cancer Registry of South Africa, 2004.
- C. F. Heyns, S. Mathee, A. Isaacs, A. Kharwa, P. M. de Beer, and M. A. Pretorius, “Problems with prostate specific antigen screening for prostate cancer in the primary healthcare setting in South Africa,” BJU International, vol. 91, no. 9, pp. 785–788, 2003.
- C. F. Heyns, M. Fisher, A. Lecuona, and A. van der Merwe, “Prostate cancer among different racial groups in the western cape: presenting features and management,” South African Medical Journal, vol. 101, no. 4, pp. 267–270, 2011.
- S. M. Gueye, C. M. Zeigler-Johnson, T. Friebel et al., “Clinical characteristics of prostate cancer in African Americans, American whites, and Senegalese men,” Urology, vol. 61, no. 5, pp. 987–992, 2003.
- C. M. Zeigler-Johnson, H. Rennert, R. D. Mittal et al., “Evaluation of prostate cancer characteristics in four populations worldwide,” The Canadian Journal of Urology, vol. 15, no. 3, pp. 4056–4064, 2008.
- L. Niang, C. N. Kouka, M. Jalloh, and S. M. Gueye, “Screening for prostate cancer by digital rectal examination and PSA determination in Senegal,” ISRN Oncology, vol. 2011, Article ID 943704, 4 pages, 2011.
- M. C. Parkinson, “Pre-neoplastic lesions of the prostate,” Histopathology, vol. 27, no. 4, pp. 301–311, 1995.
- R. A. Kittles, W. Chen, R. K. Panguluri et al., “CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification?” Human Genetics, vol. 110, no. 6, pp. 553–560, 2002.
- S. J. Plummer, D. V. Conti, P. L. Paris, A. P. Curran, G. Casey, and J. S. Witte, “CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 12, no. 9, pp. 928–932, 2003.
- C. Zeigler-Johnson, T. Friebel, A. H. Walker et al., “CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer,” Cancer Research, vol. 64, no. 22, pp. 8461–8467, 2004.
- A. Stone, L. D. Ratnasinghe, G. L. Emerson et al., “CYP3A43 Pro340 Ala polymorphism and prostate cancer risk in African Americans and Caucasians,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 5, pp. 1257–1261, 2005.
- T. R. Rebbeck, H. Rennert, A. H. Walker et al., “Joint effects of inflammation and androgen metabolism on prostate cancer severity,” International Journal of Cancer, vol. 123, no. 6, pp. 1385–1389, 2008.
- J. M. Jaffe, S. B. Malkowicz, A. H. Walker et al., “Association of SRD5A2 genotype and pathological characteristics of prostate tumors,” Cancer Research, vol. 60, no. 6, pp. 1626–1630, 2000.
- M. S. Cicek, D. V. Conti, A. Curran et al., “Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR,” Prostate, vol. 59, no. 1, pp. 69–76, 2004.
- V. M. Hayes, G. Severi, E. J. D. Padilla et al., “5α-reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia,” International Journal of Cancer, vol. 120, no. 4, pp. 776–780, 2007.
- C. Neslund-Dudas, C. H. Bock, K. Monaghan et al., “SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness,” Prostate, vol. 67, no. 15, pp. 1654–1663, 2007.
- C. Paz-y-Miño, T. Witte, P. Robles, W. Llumipanta, M. Díaz, and M. Arévalo, “Association among polymorphisms in the steroid 5α-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population,” Cancer Genetics and Cytogenetics, vol. 189, no. 2, pp. 71–76, 2009.
- P. Fernandez, P. D. de Beer, L. D. van der Merwe, and C. F. Heyns, “Genetic variations in androgen metabolism genes and associations with prostate cancer in South African men,” South African Medical Journal, vol. 100, no. 11, pp. 741–745, 2010.
- C. M. Zeigler-Johnson, A. H. Walker, B. Mancke et al., “Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4,” Human Heredity, vol. 54, no. 1, pp. 13–21, 2002.
- P. Fernandez, P. M. de Beer, L. van der Merwe, and C. F. Heyns, “COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men,” Carcinogenesis, vol. 29, no. 12, pp. 2347–2350, 2008.
- M. L. Freedman, D. Reich, K. L. Penney et al., “Assessing the impact of population stratification on genetic association studies,” Nature Genetics, vol. 36, no. 4, pp. 388–393, 2004.
- A. B. Spurdle, B. Goodwin, E. Hodgson et al., “The CYP3A4* 1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer,” Pharmacogenetics, vol. 12, no. 5, pp. 355–366, 2002.
- N. M. Makridakis, R. K. Ross, M. C. Pike et al., “Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA,” The Lancet, vol. 354, no. 9183, pp. 975–978, 1999.
- N. Makridakis, R. K. Ross, M. C. Pike et al., “A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase,” Cancer Research, vol. 57, no. 6, pp. 1020–1022, 1997.
- V. Petrow, “The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications,” Prostate, vol. 9, no. 4, pp. 343–361, 1986.
- K. Stefflova, M. C. Dulik, A. A. Pai et al., “Evaluation of group genetic ancestry of populations from Philadelphia and Dakar in the context of sex-biased admixture in the Americas,” PLoS ONE, vol. 4, no. 11, Article ID e7842, 2009.